{"id":36734,"date":"2025-07-04T17:58:38","date_gmt":"2025-07-04T09:58:38","guid":{"rendered":"https:\/\/flcube.com\/?p=36734"},"modified":"2025-07-04T17:58:39","modified_gmt":"2025-07-04T09:58:39","slug":"sino-biopharmaceuticals-recombinant-factor-viia-n01-approved-by-nmpa-for-hemophilia-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36734","title":{"rendered":"Sino Biopharmaceutical&#8217;s Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment"},"content":{"rendered":"\n<p>China\u2019s Sino Biopharmaceutical Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its recombinant human coagulation factor VIIa N01. The drug is indicated for the treatment of bleeding episodes in congenital hemophilia patients aged 12 and above with factor VIII or IX inhibitors >5 Bethesda units (BU). This approval makes it the first home-grown biologic product of its kind in China.<\/p>\n\n\n\n<p><strong>Clinical Trial Results<\/strong><br>The NMPA\u2019s approval is supported by results from a multi-center Phase III study conducted in hemophilia patients with inhibitors. The study involved 60 subjects and covered 559 bleeding episodes. Among 551 evaluable bleeding events, the drug demonstrated an effective hemostasis rate of 88.93%. Developed through independently established cell culture, separation and purification, and formulation processes, the drug has obtained two Chinese invention patents and has undergone multiple batches of commercial production validation, ensuring consistent quality.<\/p>\n\n\n\n<p><strong>Complementary Product Launch<\/strong><br>The launch of recombinant human coagulation factor VIIa N01 complements Sino Biopharmaceutical&#8217;s previously approved recombinant human coagulation factor VIII (An Heng Ji). Together, these products address the full spectrum of treatment needs for hemophilia patients, from routine replacement therapy to inhibitor management, potentially benefiting a broader population of patients.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2025070301807_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025070301807_c.\"><\/object><a id=\"wp-block-file--media-d7c24402-8e90-46a0-b320-58a0b3a49dfd\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2025070301807_c.pdf\">2025070301807_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/2025070301807_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d7c24402-8e90-46a0-b320-58a0b3a49dfd\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2019s Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received marketing approval from the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":36736,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[908,15,313],"class_list":["post-36734","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hkg-1177","tag-product-approvals","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical&#039;s Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its recombinant human coagulation factor VIIa N01. The drug is indicated for the treatment of bleeding episodes in congenital hemophilia patients aged 12 and above with factor VIII or IX inhibitors &gt;5 Bethesda units (BU). This approval makes it the first home-grown biologic product of its kind in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36734\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical&#039;s Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment\" \/>\n<meta property=\"og:description\" content=\"China\u2019s Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its recombinant human coagulation factor VIIa N01. The drug is indicated for the treatment of bleeding episodes in congenital hemophilia patients aged 12 and above with factor VIII or IX inhibitors &gt;5 Bethesda units (BU). This approval makes it the first home-grown biologic product of its kind in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36734\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-04T09:58:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-04T09:58:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0416.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36734#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36734\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical&#8217;s Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment\",\"datePublished\":\"2025-07-04T09:58:38+00:00\",\"dateModified\":\"2025-07-04T09:58:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36734\"},\"wordCount\":215,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36734#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0416.webp\",\"keywords\":[\"HKG: 1177\",\"Product approvals\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36734#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36734\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36734\",\"name\":\"Sino Biopharmaceutical's Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36734#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36734#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0416.webp\",\"datePublished\":\"2025-07-04T09:58:38+00:00\",\"dateModified\":\"2025-07-04T09:58:39+00:00\",\"description\":\"China\u2019s Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its recombinant human coagulation factor VIIa N01. The drug is indicated for the treatment of bleeding episodes in congenital hemophilia patients aged 12 and above with factor VIII or IX inhibitors >5 Bethesda units (BU). This approval makes it the first home-grown biologic product of its kind in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36734#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36734\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36734#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0416.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0416.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sino Biopharmaceutical's Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36734#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical&#8217;s Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical's Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its recombinant human coagulation factor VIIa N01. The drug is indicated for the treatment of bleeding episodes in congenital hemophilia patients aged 12 and above with factor VIII or IX inhibitors >5 Bethesda units (BU). This approval makes it the first home-grown biologic product of its kind in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36734","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical's Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment","og_description":"China\u2019s Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its recombinant human coagulation factor VIIa N01. The drug is indicated for the treatment of bleeding episodes in congenital hemophilia patients aged 12 and above with factor VIII or IX inhibitors >5 Bethesda units (BU). This approval makes it the first home-grown biologic product of its kind in China.","og_url":"https:\/\/flcube.com\/?p=36734","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-04T09:58:38+00:00","article_modified_time":"2025-07-04T09:58:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0416.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36734#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36734"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical&#8217;s Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment","datePublished":"2025-07-04T09:58:38+00:00","dateModified":"2025-07-04T09:58:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36734"},"wordCount":215,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36734#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0416.webp","keywords":["HKG: 1177","Product approvals","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36734#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36734","url":"https:\/\/flcube.com\/?p=36734","name":"Sino Biopharmaceutical's Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36734#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36734#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0416.webp","datePublished":"2025-07-04T09:58:38+00:00","dateModified":"2025-07-04T09:58:39+00:00","description":"China\u2019s Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its recombinant human coagulation factor VIIa N01. The drug is indicated for the treatment of bleeding episodes in congenital hemophilia patients aged 12 and above with factor VIII or IX inhibitors >5 Bethesda units (BU). This approval makes it the first home-grown biologic product of its kind in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36734#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36734"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36734#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0416.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0416.webp","width":1080,"height":608,"caption":"Sino Biopharmaceutical's Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36734#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical&#8217;s Recombinant Factor VIIa N01 Approved by NMPA for Hemophilia Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0416.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36734"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36734\/revisions"}],"predecessor-version":[{"id":36737,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36734\/revisions\/36737"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36736"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36734"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36734"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}